Glaxo (GSK) Up 8% Since Last Earnings Report: Can It Continue?
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Financial Express on MSN3h
Complan grows up, Zydus takes kids’ health drink into adult’s wellness market
Discover how Zydus Wellness is reinventing Complan, the iconic health drink, by expanding its target audience, leveraging ...
Nasdaq6d
Glaxo (GSK) Up 8% Since Last Earnings Report: Can It Continue?
Will the recent positive trend continue leading up to its next earnings release, or is Glaxo due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take ...
'Prescription medication made me a gambling addict'
Phil Stevens, from Hampshire, said he developed an addiction to gambling and spending after taking prescription medication ...
Graham Richards, Oxford head of chemistry whose business flair earned the university millions
Professor Graham Richards, who has died aged 85, was chairman of the chemistry department of Oxford University, a veteran ...
Business Today2d
Glaxosmithkline Pharmaceuticals Ltd (GLAXO) Share Price
What is the share price of Glaxosmithkline Pharmaceuticals Ltd (GLAXO) today on NSE? As on Mar 12, 2025, Glaxosmithkline Pharmaceuticals Ltd (GLAXO)’s share price on NSE is Rs 2683.1 What is the ...
STAT1d
Lilly CEO got a big payday (and an Olympics treat)
Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...
STAT1d
Warren asks HHS watchdog to investigate GSK over its asthma inhaler maneuvers
After a year of controversy and complaints, Sen. Elizabeth Warren is asking a federal watchdog to investigate GSK over its ...
BioSpace1d
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...